Eterna Therapeutics Inc (ERNA)
$1.01
Performance
- $0.95$1.06$1.01
5.84%
Downside
Day's Volatility :10.28%
Upside
4.72%
- $0.84$2.63$1.01
16.82%
Downside
52 Weeks Volatility :68.0%
Upside
61.52%
Returns
| Period | Eterna Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -51.68% | 0.0% |
6 Months | -53.03% | 0.0% |
1 Year | -53.07% | 0.0% |
3 Years | -89.06% | -21.1% |
Highlights
Market Capitalization | 5.8M |
Book Value | - $1.58 |
Earnings Per Share (EPS) | -4.43 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -10491.49% |
Return On Assets TTM | -29.42% |
Return On Equity TTM | -1154.18% |
Revenue TTM | 162.0K |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -21.9M |
Diluted Eps TTM | -4.43 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 197.03%
Technicals Summary
Sell
Neutral
Buy
Eterna Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eterna Therapeutics Inc | -32.67% | -53.03% | -53.07% | -89.06% | -85.41% |
 Regeneron Pharmaceuticals, Inc. | -11.94% | 13.03% | 20.97% | 85.64% | 232.53% |
 Novo Nordisk A/s | -12.38% | -3.12% | 17.52% | 138.65% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 7.18% | 92.5% | 69.12% | 39.45% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.75% | 21.23% | 29.84% | 165.64% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eterna Therapeutics Inc | NA | NA | NA | 0.0 | -11.54 | -0.29 | NA | -1.58 |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eterna Therapeutics Inc | Sell | $5.8M | -85.41% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Insights on Eterna Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 122.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.4% return, outperforming this stock by 128.5%
Institutional Holdings
Cypress Point Wealth Management, LLC
1.74%Naviter Wealth, LLC
1.46%Sippican Capital Adivsors
1.35%CI Private Wealth LLC
0.93%Vanguard Group Inc
0.48%Geode Capital Management, LLC
0.44%
Company Information
brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.
Organization | Eterna Therapeutics Inc |
Employees | 8 |
CEO | Ms. Sandra M. Gurrola |
Industry | Healthcare |
